

OncoMark
OncoMark has developed a novel prognostic test for breast cancer that identifies those patients who do not require chemotherapy, a market worth €1.1BN.
- Stage Product In Development
- Industry Medical Devices and Equipment
- Location Dublin, Ireland
- Currency EUR
- Founded January 2007
- Employees 8
- Website oncomark.com
Company Summary
OncoMark has licenced a proven technology with excellent proof of concept data, which was developed by leading scientists in TCD & UCD. The company will fast-track product development (aiming for CE marking in 2.5 years), aided by a prestigious EU Horizon 2020 SME instrument grant starting in Feb 2016. The development has a clear regulatory & reimbursement pathway, resulting in a premium test with significant margin and return of investment.